Patent · US Active

Puma protein expression vector and use thereof in gene therapy

US10449232B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignees

HOSPICES CIVILS DE LYON · FR
The Regents of the University of California · US
UNIVERSITE CLAUDE BERNAD LYON 1 · FR
INSTITUT ENSEIGNEMENT SUPERIEUR ET RECHERCHE EN ALIMENTATION SANTE ANIMALE SCIENCES AGRONOMIQUES ET ENVIRONNEMENT (VET AGRO SUP) · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

Pierre Miossec · Bron, FR
Saw-See Hong · Montpellier, FR
Gary Firestein · Del Mar, US

Key dates

Filing date	Oct 7, 2014
Grant date	Oct 22, 2019
Priority date	—
Expiry date	Oct 7, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2810/855
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a viral vector for expression of the cell death-inducing PUMA protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the PUMA protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (CAR).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.